Abiopharma

🔍 Matrix Capital Management Company, LP (Executive)

Company: Zentalis Pharmaceuticals, Inc. (ZNTL)

Report Date: 2025-12-15

Detailed Transactions and Holdings:

• Sold 7,500,000 shares of Common Stock, par value $0.001 per share at $1.33 per share (Direct)
  Date: 2025-12-15 | Code: S | equity_swap_involved: 0 | shares_owned_after: 6,459,973.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.
• F2: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.